Supernus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	718.95	661.82	607.52	667.24	579.78
Revenue Growth (YoY)	8.63%	8.94%	-8.95%	15.09%	11.41%
Cost of Revenue	74.56	77.91	83.78	87.22	75.06
Gross Profit	644.39	583.91	523.74	580.02	504.71
Selling, General & Admin	485.56	321.58	336.36	377.22	304.76
Depreciation & Amortization Expenses	89.46	77.98	82.39	82.63	29.99
Research & Development	106.24	108.8	91.59	74.55	90.47
Other Operating Expenses	25.42	-6.11	18.67	-0.51	-6.53
Total Operating Expenses	706.67	502.25	529.01	533.89	418.69
Operating Income	-62.28	81.67	-5.27	46.12	86.03
Total Non-Operating Income (Expense)	13.25	16.2	8.04	14.62	-12.85
Pretax Income	-49.03	97.87	2.77	60.74	73.18
Provision for Income Taxes	-10.48	24.01	1.45	0.03	19.75
Net Income	-38.55	73.87	1.32	60.71	53.42
Net Income to Common	-38.55	73.87	1.32	60.71	53.42
Net Income Growth	-	5512.84%	-97.83%	13.64%	-57.92%
Shares Outstanding (Basic)	56	55	55	54	53
Shares Outstanding (Diluted)	56	56	56	62	54
Shares Change (YoY)	0.88%	0.81%	-10.01%	13.47%	1.24%
EPS (Basic)	-0.68	1.34	0.02	1.13	1.01
EPS (Diluted)	-0.68	1.32	0.02	1.04	0.98
EPS Growth	-	6500.00%	-98.08%	6.12%	-58.48%
Free Cash Flow	45.99	171.23	110.53	116.41	125.08
Free Cash Flow Growth	-73.14%	54.91%	-5.05%	-6.93%	-7.15%
Free Cash Flow Per Share	0.81	3.06	1.99	1.89	2.30
Gross Margin	89.63%	88.23%	86.21%	86.93%	87.05%
Operating Margin	-8.66%	12.34%	-0.87%	6.91%	14.84%
Profit Margin	-5.36%	11.16%	0.22%	9.10%	9.21%
FCF Margin	6.40%	25.87%	18.19%	17.45%	21.57%
EBITDA	29.28	162.08	79.59	131.67	118.62
EBITDA Margin	4.07%	24.49%	13.10%	19.73%	20.46%
EBIT	-62.28	81.67	-5.27	46.12	86.03
EBIT Margin	-8.66%	12.34%	-0.87%	6.91%	14.84%
Effective Tax Rate	21.37%	24.53%	52.47%	0.05%	26.99%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q